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Abstract Primary non-Hodgkin’s lymphoma of the cervix is
a rare disease, of which a subgroup of follicular lymphoma
constitutes only 8.5%. There is not an established treatment
protocol neither for primary cervical lymphoma nor for its
follicular subgroup. We presented a case with Ann Arbor
stage IEA (Extra-nodal involvement and absence of weight
loss, fever, night sweat) primary follicular lymphoma of the
cervix. She was treated with chemotherapy followed by pelvic
radiotherapy. Upon relapse with a nodal neck mass, she was
treated with rituximab alone. She remained well for 23
months after rituximab. In the 39 months of follow-up, there
was no evidence of disease. In the light of our case, we
reviewed the reported cases of primary follicular lymphoma
of the cervix while discussing their treatment protocols and
the cases of primary cervix lymphoma treated with rituximab.
Keywords Primary cervix lymphoma . Follicular .
Radiotherapy . Chemotherapy
Introduction
Primary non-Hodgkin’s lymphoma (NHL) of the cervix is
extremely rare. Only 0.5% of extranodal lymphomas in
women are likely to originate in the female genital tract [1,
2]. Until now, more than 130 cases of primary NHL of the
cervix have been reported. The most common histological
subtype is diffuse large B-cell lymphoma [3]. Only 11 cases
with low-grade follicular lymphoma of the cervix were re-
ported comprising 8.5% of the primary cervix lymphomas
[2–9].
In the cervical lymphoma, the median age at presentation is
44 years, ranging from 27 to 80 years [5, 10]. The most
frequent complaint is abnormal vaginal bleeding [7]. Fever,
night sweats, and weight loss are usually not the features of
primary lymphoma of the cervix. Other gynecologic symp-
toms can occur including pelvic pain, postcoital bleeding,
postmenopausal bleeding, and dyspareunia [11–13]. Differ-
ential diagnosis of primary cervical lymphomas includes
benign inflammatory and malignant disease such as cervical
carcinomas, sarcomas, and lymphoma-like lesions [3, 14,
15]. For a definitive diagnosis, a deep cervical biopsy with
histopathological evaluations and immunophenotyping are
required [14, 15]. Because such located lymphomas are
subepithelial and unless there is ulceration and exfoliation,
Papanicolaou smear plays a very insignificant role in the
diagnosis of cervical lymphoma [7]. Ann Arbor stage, size,
and extent of disease, age, number of extranodal sites, per-
formance status, serum lactate dehydrogenase (LDH) values,
and grade of lymphoma are significant prognostic features
[4, 6, 11, 16].
Because of the rarity, there is not an established treatment
protocol for primary NHL of the cervix. Radiotherapy,
chemotherapy, and surgery, either alone or in combination,
are the mainstay of treatment [10–12, 17, 18]. Some suggested
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that chemotherapy followed by pelvic radiotherapy appar-
ently is the best option with better survival rate [6, 19].
Moreover, there is not enough experience on the treatment
of primary low-grade follicular lymphoma of the cervix in
the literature. Follicular lymphoma is characterized by contin-
uous relapses with shorter response duration and a shorter
survival after each relapse [20]. Treatment options include
watchful waiting, oral alkylating agents, purine nucleoside
analogues, combination chemotherapy, radiotherapy, interfer-
on, and monoclonal antibodies.
Rituximab, which is a monoclonal antibody, is used for
treatment of CD20+ lymphomas. Rituximab is also used for
treatment of primary NHL of the cervix [21]. In the literature,
there are six cases with large B-cell histology. They were
treated with chemotherapy (CT) + rituximab as a first-line
regimen with promising results [17, 18, 22]. However, there
was only one patient with follicular lymphoma of the cervix
who received CT+ rituximab as a first-line treatment [9].
In this paper, we presented a case with Ann Arbor stage
IEA primary follicular NHL of the cervix [23]. She was
first treated with chemotherapy followed by pelvic radio-
therapy. Upon a nodal relapse in the neck, she was treated
only with rituximab. She remained well for 23 months after
rituximab. In the light of our case, we reviewed the available
reported cases of follicular lymphoma of the cervix while
discussing their treatment protocols and the cases of primary
cervix NHL treated with rituximab.
Case report
A 67-year-old postmenopausal woman presented with ab-
normal vaginal bleeding and back pain for 2 months. Her
past medical, gynecologic, and family histories were all
unremarkable. At gynecological examination, there was an
exophytic tumor arising from the cervix with spread to the
parametrium but not to the pelvic sidewalls. Vaginal ultra-
sound revealed a cervical mass measuring 75×60 mm in
diameter. Computed tomography (CT) and magnetic reso-
nance imaging (MRI) showed diffuse enlargement and
enhancement of the cervix. The cervical tumor was classified
clinically as a FIGO stage IIB. Papanicolaou smear results
were normal. Cervical biopsy demonstrated low-grade follic-
ular NHL according to WHO classification [24].
Systemic examination did not show any other abnormal
findings. Physical examination, staging investigations in-
cluding routine hematology and biochemistry tests, chest
radiograph, CT of neck–thorax–abdomen regions, immuno-
globulin pattern and electrophoresis, bone marrow aspira-
tion, and biopsy showed no evidence of lymphoma or other
disease in other parts of the body. The patient was staged IEA
according to the Ann Arbor staging system for extranodal
lymphomas [23].
She was treated with three courses of combination che-
motherapy including cyclophosphamide, doxorubicin, vin-
cristine, and prednisone (CHOP). After chemotherapy, MRI
showed 70% decrease in the cervical mass. Because she had
myelosuppression and particularly granulocytopenia after
three cycles of therapy, bone marrow aspiration and biopsy
were repeated. There was no involvement of the bonemarrow.
Subsequently, she was treated with external radiotherapy
(ERT) to the whole pelvis with a box technique using 25 MV
linear accelerator. A total dose of 4,140 cGy in 23 daily
fractions was applied. She tolerated well with no significant
side effects. On follow up, she was in good condition. Radio-
logical and clinical assessments including cervical biopsy re-
vealed no evidence of disease, and the patient remained in
complete remission.
After 16 months after the initial diagnosis, a relapse of a
4-cm lymphadenopathy in the neck occurred. A biopsy from
the lymphadenopathy again reported as low-grade follicular
NHL. Further investigations did not reveal any other evidence
of recurrence. She was designated as relapse stage I with a
continuing complete response at an irradiated site. Because of
the bone marrow toxicity that occurred during the previous
treatment, the patient being at an old age and refusing the
multidrug chemotherapy regimen, eight cycles of rituximab
alone were administered with no adverse events. There was a
complete remission after rituximab. The patient remains well
at 23 months after rituximab. In the 39 months of follow-up,
there was no evidence of disease.
Discussion
Primary cervical NHLs are defined as the lymphomas that
localize at the cervix without any myometrial involvement
and any evidence of leukemia at the time of diagnosis [4].
Etiology and pathogenesis of primary cervical NHL are
unknown, although there might be a possible association
be-tween chronic inflammation and lymphomas [25]. CT
and MRI are useful in diagnosis and staging, but their
specificity is low [9, 13]. Cervical biopsy and immunophe-
notyping are necessary to differentiate primary cervical NHL
from benign and malignant disease of the cervix [3, 14, 15,
19]. There is no consensus for staging of lymphoma of the
cervix. Both FIGO (International Federation of Gynaecology
and Obstetrics) and the Ann Arbor staging systems for
extranodal lymphoma are used [24]. The natural history of
NHL of the cervix varies with histological types. The most
common histological subtype is diffuse large B-cell lym-
phoma [3, 10, 19]. Reviewing the cases reported in the
literature, the follicular subgroup comprises only 8.5% of the
primary cervix NHL cases. Other rare B-cell lymphomas in
the cervix are marginal zone B-cell lymphoma and mucosa-
associated lymphoid tissue lymphoma [3, 19].
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Prognosis of extranodal lymphomas is usually poorer than
nodal lymphomas because of inaccurate or delayed diagnosis
[26]. However, prognosis of primary cervix NHL, if
diagnosed at earlier stages, may be excellent compared to
other gynecologic malignancies [9, 21]. In the cervix
lymphoma, the stage and grade of the disease are important
predictors of survival. In three large series of primary cervix
lymphoma, survival was found to be better in stage IE
compared to higher stages, but it was statistically significant
only in one of them (stage IE, 89% versus stages IIE and IV,
20%) [2, 4, 6]. The grade of the disease is statistically
important when comparing the survival between low-grade
and high-grade diffuse lymphomas [2, 4, 6]. However, the
prognostic significance of the different histological types is
still unclear [4]. Based on the combined data of studies, the
5-year survival rate of patients with a follow-up of at least 5
years is approximately 80% [4–6, 16]. One study correlated
survival with International Index score, which assesses the
age of the patient, Ann Arbor stage, number of extranodal
sites, performance status, and serum LDH values [6].
Patients with low scores had statistically significant better
survival rates than those with high scores.
The management strategy of primary NHL of the cervix is
not clear because of rarity of the disease, different histopath-
ological subtypes, and limited experiences. According to
several case reports and a few case series, treatment regimens
of primary NHL of the cervix include chemotherapy alone,
radiotherapy alone, or radiotherapy combined with either che-
motherapy or surgery [4, 6, 11–19, 21, 25, 27–34]. In earlier
reports, because of high response rate and low morbidity,
radiotherapy was used as the first-line treatment for stage IE
disease [2, 4, 5, 28, 29]. From 1960 to 1990, 76% of the cases
of stage IE cervical NHL received radiotherapy [5]. Since
1974, 63% of all primary cervix NHL cases were treated with
radiotherapy alone or in combination with surgery and/or
chemotherapy. Some suggested that the survival rates in the
earlier stage of low and intermediate grade cervical lympho-
mas are excellent with either surgery, chemotherapy, or
radiotherapy. To preserve reproductive function in such young
patients and/or to prevent the micrometastasis, combination
chemotherapy alone was advocated [14–16, 21]. If involved
field radiotherapy (IF-XRT) alone is to be applied in young
patients, then ovarian transposition to preserve reproductive
and gonadal function shall be considered [10].
According to the recent publications of early stage primary
cervix NHL, chemotherapy is suggested before the local
treatments to prevent the occult disease not detectable by
imaging and to improve the treatment results. The CHOP
regimen, which is proved to be effective, is generally used
[35]. Recent studies suggest that management with combi-
nation of chemotherapy and after pelvic radiotherapy
apparently is the best option with better survival and a 5-
year survival rate of up to 100% in some series of primary
NHL of the cervix [3, 6, 10, 16, 18, 19, 29, 36, 37].
Reviewing the literature, 36 patients received combination
treatment of chemotherapy and external radiotherapy, and
only two of them died of disease at the second and ninth
month after diagnosis (Table 1) [3, 6, 9, 10, 13, 16, 18, 19,
22, 25, 27, 30–34, 36–42].
The cervix is a very unusual extranodal region, and only 11
cases with follicular histology were reported in the literature.
The most common extranodal locations of follicular lympho-
mas are the head and neck, skin, and gastrointestinal system.
Follicular lymphoma is characterized by a pattern of con-
tinuous relapses with shorter response duration and a shorter
survival after each relapse [43]. There are various options for
treatment including watchful waiting, oral alkylating agents,
purine nucleoside analogues, combination chemotherapy,
radiotherapy, interferon, monoclonal antibodies, and autolo-
gous or allogeneic bone marrow or peripheral stem cell
transplantation.
The usual therapy for stage I–II low-grade follicular NHL
patients is a moderate dose IF-XRT [44, 45]. Many large
series reported similar results with 28–53% of patients free
from recurrence, overall survival rates of 60–70% after ten or
more years, and a low risk of recurrence beyond this time
[44, 46, 47]. Relapses usually occur at unirradiated sites and
within the first 5 years. The dominant sites of failure are
systemic, attributable likely to occult disease, which is left
untreated [46, 47].
An alternative approach to improve the efficacy of IF-
XRT is the addition of chemotherapy. The CHOP regimen
is also used as the treatment regimen for low-grade
lymphomas [35, 48]. The retrospective studies suggested
possible benefit from the use of combined modality therapy
in these patients [49, 50]. However, randomized studies
regarding effectiveness of chemotherapy at the early stages
of the low-grade follicular NHL did not show a statistically
significant result because of the inadequate number of
patients and inability to follow up for a long time [45, 51–
53]. Comparing the series of radiation alone treatment with
the long-term results of combined modality treatment from
MD Anderson, the combined modality approach appears to
provide a 20–30% improvement in the likelihood of
remaining free of recurrent disease 10 years after treatment
[54]. The 10-year survival after relapse was 46%. This
potentially improved outcome was achieved without appar-
ent long-term toxicity. However, studies evaluating the
treatment results and features of the rarely seen follicular
subgroup of extranodal lymphoma are insufficient. Therefore,
it is not clear how to treat rarely seen extranodal follicular
lymphomas in the literature.
Until now, there are 11 reported cases with primary low-
grade follicular lymphoma of the cervix [2–9]. Patients
were treated with radiotherapy, chemotherapy, and surgery
in varying combinations (Table 2). Seven of them are in
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Stage I, two in Stage II, one in Stage III, and one in Stage
IV. To 6 (54.5%) out of 11 follicular lymphoma patients,
external radiotherapy was applied. While radiotherapy was
used in three patients after surgery, in one patient combined
with chemotherapy, and in two other combined postoper-
atively with chemotherapy; surgery alone was done for
three (27%) patients. In eight (73%) patients, the diagnosis
was done by surgery. While one (9%) patient was under
wait and watch, one (9%) received chemotherapy alone.
Total dose of radiotherapy varied between 30 and 45 Gy.
Follow-up time ranged from 4 months to 14 years. Even in
our case, there was an issue of nodal relapse in the 16th
Table 1 Primary cervix lymphoma cases treated with chemoradiotherapy in the literature
References Number Age Ann Arbor
stage
NHL subtype Treatment Follow-up
(month)
Response
Cantu de Leon et al.
[42]
1 56 IIE DLBC CT(CHOP)-P ERT 6 CR
Hariprasad et al. [10] 2 47 IE DLBC CT(CHOP)-P ERT 13 CR
Chan et al. [37] 3 40 IVEA G CT(CHOP)-P ERT 120 NED
Heredia et al. [34] 4 32 IEA Diffuse mix B cell CT(CHOP)-P ERT 61 NED
5 31 IIEA Diffuse mix B cell CT(CHOP)-S-ERT 15 NED
Kendrick et al. [22] 6 47 IIE Int grade LBC CT(CHOP-RIT)-P
ERT
16 NED
Thyagarajan et al. [13] 7 41 IVE High grade B cell CT-P ERT 7 NED
Kahlifa et al. [41] 8 32 IEA DLBC CT(CHOP-RIT)-P
ERT
10 CR
Bode et al. [9] 9 46 IEA FL CT(CEOP-RIT)-P
ERT
10 CR
Yokoyama et al. [31] 10 55 IIEA G CT(CEOP-RIT)-P
ERT
12 NED
Vang et al. [19] 11 57 IIEA DLBC CT-P ERT 120 NED
Tunca et al. [30] 12 22 IEA G CT-P ERT 30 NED
Mansouri et al. [40] 14 34 IEA I CT-P ERT 48 CR
Castaldo et al. [38] 15 33 DSC S-CT-ERT 9 DOD
Strang et al. [32] 16 77 IE Centroblastik CT(COP)-P ERT 36 NED
Khoury et al. [33] 17 37 IE DLC CT(CHOP)-P ERT 96 NED
18 46 CT(COP)-P ERT 102 NED
Makarewicz and
Kuzminska [27]
19 37 IEA DBC CC CT(COP)-P ERT 96 NED
20 65 IEA B-cell
lymphoblastic
CT(COP)-P ERT 36 NED
Stroh et al. [6] 21 53 IEA G CT(CHOPB)-P ERT 172.8 NED
22 64 IEA CT(CHOPB)-P ERT 164.4 NED
23 39 IIEA CT(CHOPB)-P ERT 141.6 NED
24 35 IIIEB CT(CHOPB)-P ERT 117 NED
25 66 IEA CT(CHOP)-P ERT 60 NED
26 67 IEA CT(ASHAP)-P ERT 18 NED
Papadopoulos et al.
[39]
27 IEB H S-CT(CHOP)-PERT 48 NED
Aozasa et al. [25] 28 71 NA DLBC CT-P ERT 2 DOD
Vang et al. [3] 29 39 IE G CT-P ERT 7 NED
30 57 IIEA G CT-P ERT 120 NED
31 57 IIEA G CT-P ERT 60 NED
32 52 IEA DLBC CT-P ERT 12 NED
33 61 IIEA FL S-CT-ERT 72 NED
34 67 IEA DLBC CT-P ERT 60 NED
Chandy et al. [36] 35 50 IEA H CT-P ERT 24 NED
Cohn et al. [18] 36 22 IE DLBC CT(CHOP)-P ERT 14 NED
Present 37 67 IE FL CT(CHOP)-P ERT 39 NED
CT Chemotherapy, P ERT pelvic external radiotherapy, S surgery, RIT rituximab, FL follicular lymphoma, DLBC diffuse large B cell, DLC diffuse
large cell, Int grade LBC intermediate grade large B cell, G malignant lymphoma diffuse, H malignant lymphoma large cell, I malignant
lymphoma lymphoblastic, CC centroblastic centrocytic, NED no evidence of disease, DOD died of disease, CR complete remission
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month. As follow-up times were very short in some cases,
complete evaluation of relapses was limited. All patients
were alive. Eight patients had no evidence of disease, two
had the stable disease, and one was alive with disease at the
end of their follow up time.
Rituximab was the first monoclonal antibody, which has
been registered for the treatment of B-cell lymphomas. The use
of rituximab has been rapidly incorporated in clinical practice
because of its significant clinical activity and few adverse
effects [55]. Randomized studies have demonstrated its
activity in untreated or relapsed cases of follicular lymphoma
either as a single agent or in combination with chemotherapy
[56–61]. Despite its widespread use, the optimal schedule for
drug administration is still not completely defined.
Table 3 Lymphoma of the cervix treated with rituximab
Author (year) Number Age Ann Arbor
stage
First-line treatment Treatment of relapse Survival




Kendrick JE (2005) [22] 2 47 IIE 4CHOP-RIT-ERT (50.4
Gy P+ 9 Gy boost)
No NED
16 months










5 49 IIE S-6CHOP-RIT No NED
32 months
Cohn DE (2007) [18] 6 64 IE 5CHOP-RIT No SD
13 months




Present (2007) 8 67 IEA CT-ERT (3CHOP)-
(41.4 Gy P)




CT Chemotherapy, ERT external radiotherapy, RIT rituximab, S surgery, HDCT +ASCT high dose chemotherapy-autologous stem cell transplant,
NED no evidence of disease, SD stable disease, P pelvis, PA paraaortic
Table 2 Primary low grade follicular lymphoma of the cervix from the literature







Charlton I (1974) [2] 1 34 – S No AWD 10 years
Harris NL (1984) [4] 2 49 IEA S No NED 14 years
3 43 IEA S-ERT (30 Gy P) No NED
4 50 IEA S-ERT (30 Gy
P+ 18 Gy wall)
No NED 3.3 years
5 26 IEA S No NED 4 years
Muntz HG (1991) [5] 6 57 IEA S-ERT (45 Gy
P+ 40 Gy PA)
No NED 4.5 years
Stroh EL (1995) [6] 7 62 IIEA S-ERT-CT (30 Gy P+10
Gy I)-(CHOP-Bleo)
No NED 18 months
Grace A (1999) [7] 8 52 IIIEA Wait and watch No SD 4 months
Vang R (2000) [3] 9 61 IIEA S-ERT-CT No NED 6 years
Bode MK (2002) [9] 10 46 IEA CT-RIT-ERT (3CEOP)-
(41.4 Gy P)
No NED 10 months
Baxter NP (2003) [8] 11 75 IVE CT (Chlorambusil) No SD 6 months





CT Chemotherapy, ERT external radiotherapy, RIT rituximab, S surgery, NED no evidence of disease, SD stable disease, AWD alive with disease,
P pelvis, PA paraaortic, I inguinal
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There is less known about the primary cervix low-grade
follicular lymphoma and a drug of rituximab and its effective-
ness in the treatment of the primary disease and relapses. At
first, Bode et al. [9] presented the patient with follicular
lymphoma of the cervix who received three cycles CT com-
bined with rituximab as a primary treatment (Table 3). After
chemotherapy, the patient underwent radiotherapy with a
total dose of 41.4 Gy. Six months after the diagnosis, there
was no residual tumor in the pelvis.
There also are 6 CD 20B-cell primary cervix lympho-
mas treated with rituximab. All have taken rituximab
combined with CHOP chemotherapy as a first-line therapy
[17, 18, 22]. Only two of the six have been treated with
ERT, and within the 14th and 16th months, no evidence of
disease was noted. In one patient, rituximab combined with
chemotherapy was used, while in three others, rituximab
combined with chemotherapy were used postoperatively.
Relapse has been developed at 9 months in one patient who
has taken eight cycles of CHOP and rituximab postopera-
tively, but she was treated with high dose chemotherapy
and autologous stem cell transplantation and had no disease
at the sixth month of the transplantation [17].
In this report, we emphasized the dramatic response of a
patient to the rituximab treatment after the relapse of primary
cervix follicular lymphoma. Because of the bone marrow
toxicity that occurred during the previous treatment, the
patient being at an old age and refusing the multidrug
chemotherapy regimen, only rituximab was used for treat-
ment. The relapse regressed rapidly. The patient was disease-
free and in a good condition at the 39th month of diagnosis
and at the 23rd month after the rituximab treatment.
As a conclusion, primary cervical low-grade follicular
lymphoma is very rare disease. There is not an established
treatment protocol for early stage diseases as well as relapses.
Until the studies with larger series emerge, the results of case
reports and study series with few patients inescapably gain
importance. Systemic treatment modalities are considered to
be effective in the treatment of relapse of primary cervix
follicular lymphoma patients, while radiotherapy is consid-
ered to have a usage limited to palliation of life threatening
symptoms only.
Although for the aged patients, who refuse the toxicities of
combined systemic treatment, systemic rituximabmonotherapy
might be sufficient as an option with fewer side effects.
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